Aprinoia Therapeutics Inc., a Taipei, Taiwan-based clinical-stage neuroscience biotech company, focuses on tau, alpha-synuclein, and novel targets for neurodegenerative diseases, completed its US$11.1m Series B funding round.
The round was led by KTB Network (Korea) and DCI Partners (Japan), with participations from ShangPharma Investment Group (China) and TaiAn Technologies (Taiwan). In conjunction with the funding, Kevin Kuk Hyun Kyung from KTB Network joined the board of director.
The company intends to use the proceeds to finance preclinical and clinical development for its imaging diagnostic and therapeutic pipelines.
Led by Ming-Kuei Jang, founder and CEO, Aprinoia is a preclinical and clinical stage neuroscience biopharmaceutical company focused on neurodegenerative diseases. The company, which is advancing three diagnostic and two therapeutic product candidates, focusing on Alzheimer’s Disease, non-AD tauopathies, Lewy Body Dementia, and Parkinson’s Disease, has operations in Taiwan, China and Japan.
The most advanced tau PET imaging tracer, 18F-PM-PBB3, has shown great potential in visualising tau pathologies in Alzheimer’s and Progressive Supranuclear Palsy (PSP) patients in clinical studies conducted in early 2017.